All20222021202020192018April 8, 2022OncoMyx Presents New Data at AACR 2022 Demonstrating Multi-Armed Myxoma Virus Coordinates Tumor-Killing by Activating Innate and Adaptive Immune ResponsesRead More »March 2, 2022OncoMyx Appoints Robert Williamson Chief Business and Chief Financial OfficerRead More » December 8, 2021OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing PayloadsRead More »November 12, 2021OncoMyx Presents New Data at SITC 2021 Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme MalignanciesRead More »October 20, 2021OncoMyx Announces Presentations at SITC 2021 of New Data Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme MalignanciesRead More »October 20, 2021OncoMyx Announces Presentations at IOVC 2021 on the Use of Multi-Armed Myxoma Virus as a Novel Oncolytic ImmunotherapyRead More »August 2, 2021PharmaVoice 100: Grant McFaddenRead More »June 15, 2021OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of FloridaRead More »June 3, 2021Oncolytic Immunotherapy: Q&A With OncoMyx Therapeutics CEO Steve PottsRead More »April 12, 2021FierceBiotech — AACR: OncoMyx’s engineered rabbit pox virus shows promise in lung cancer modelRead More »April 10, 2021OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune ResponseRead More »March 19, 2021OncoMyx Announces Three Presentations of New Data for a Novel Oncolytic Immunotherapy of a Multi-Armed Myxoma Virus at AACR Virtual Annual Meeting IRead More »February 19, 2021OncoMyx to Present at Biocom’s 11th Annual Global Life Sciences Partnering ConferenceRead More »February 16, 2021OncoMyx to Present at the BIO CEO and Investor Digital ConferenceRead More » December 7, 2020OncoMyx Announces Assignment of Foundational Technology and Intellectual Property Portfolio for Oncolytic Myxoma Virus TechnologyRead More »November 17, 2020BioSpace — OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy PotentialRead More »November 13, 2020FierceBiotech — Arming the rabbit pox virus to fight cancerRead More »November 9, 2020OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020Read More »November 6, 2020OncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of DirectorsRead More »October 5, 2020OncoMyx to Present at the Chardan Virtual 4th Annual Genetic Medicines ConferenceRead More »July 31, 2020OncoMyx to Present at Inaugural LifeSci Partners Private Company Virtual Summer Symposium on August 4thRead More »February 10, 2020Skysong Innovations Completes Licensing Agreement with ASU Spinout OncoMyx TherapeuticsRead More »January 9, 2020OncoMyx Therapeutics Announces Formation of Scientific Advisory BoardRead More » August 28, 2019OncoMyx Therapeutics, Inc. to be honored with an AZBio Fast Lane AwardRead More »June 5, 2019OncoMyx Therapeutics Completes $25 Million Series A FinancingRead More » April 25, 2018Catalyst: Turning a Killer Virus into a Cure for CancerRead More »
